2021 ABAI Continuous Assessment Program Literature Review - January-June

This literature review course will help to prepare ABAI diplomates to participate in the Continuous Assessment Program (CAP). The course will include reviews of the journal articles selected for the January-June 2021 term of the CAP to help develop greater familiarity with the key concepts included in them. 

The Four presentations cover a range of critical journal articles in the following topic areas:

  • Dermatologic Conditions and Anaphylaxis
  • Conditions of the Head/Neck and Lungs
  • Food and Drug Allergy/Hypersensitivity Reactions and Eosinophilic or Gastrointestinal Disorders
  • Immune Hypersensitivity Disorders and Immunodeficiencies

Click the Program tab to access the full list of articles, with links. Please note that All CAP articles can also be accessed through the ABAI web portal.

Target Audience

  • Allergist/Immunologists participating in continuous certification with the American Board of Allergy & Immunology
  • Allied health providers working in allergy/immunology settings
  • Allergy/Immunology Fellows-in-Training preparing for initial certification
  • Other healthcare providers with an interest in allergy/immunology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate recently published research relevant to the practice of allergy/immunology
Summary
Available credit: 
  • 2.25 Attendance
    Attendance credit.
  • 2.25 CME
    CME credit.
Course opens: 
02/26/2021
Course expires: 
12/31/2021
Cost:
$0.00
Rating: 
5

All CAP articles are listed, below.
Articles can also be accessed through the ABAI web portal, and via the following PDF document:

ABAI CAP 2021 - Block 1 - Reference List.pdf

Articles for CAP 2021 – Block 1

A1 Head/Neck


• Bédard A, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology. 2019;144(1):135-143.e6. https://www.jacionline.org/article/S0091-6749(19)30426-9/fulltext
• Bielory L, et al. ICON Diagnosis and management of allergic conjunctivitis. Annals of Allergy, Asthma & Immunology. 2020;124:118-134. https://www.annallergy.org/article/S1081-1206(19)31394-8/fulltext
• Stevens WW, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(9):2812-2820.e3. https://www.sciencedirect.com/science/article/abs/pii/S2213219819304647?via%3Dihub


A2 Dermatologic


• Fishbein AB, et al. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(1):91-101. https://www.sciencedirect.com/science/article/pii/S221321981930635X?via%3Dihub
• Johal KJ, Saini SS. Current and emerging treatments for chronic spontaneous urticaria. Annals of Allergy, Asthma & Immunology. 2020;125(4):380-387. https://www.annallergy.org/article/S1081-1206(19)31054-3/pdf
• Miyaji Y, et al. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(5):1721-1724.e6. https://www.jaci-inpractice.org/article/S2213-2198(19)31018-9/pdf


A3 Lung


• Barnes PJ, et al. Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. Journal of Allergy and Clinical Immunology. 2019;144(5):1180-1186. https://www.jacionline.org/article/S0091-6749(19)30941-8/fulltext
• Cohen JM, et al. Poorly Controlled Asthma During Pregnancy Remains Common in the United States. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(8):2672-2680.e10. https://www.sciencedirect.com/science/article/abs/pii/S2213219819305008?via%3Dihub
• Generoso A, Tuong L, Oppenheimer J. Treatment strategies for the yellow zone. Annals of Allergy, Asthma & Immunology. 2019;123(4):345-351. https://www.annallergy.org/article/S1081-1206(19)30510-1/fulltext
• Mikhail I, Grayson MH. Asthma and viral infections An intricate relationship. Annals of Allergy, Asthma & Immunology. 2019;123(4):352-358. https://www.annallergy.org/article/S1081-1206(19)30464-8/fulltext


A4 Food and Drug Allergy/Hypersensitivity Reactions


• Konvinse KK, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology. 2019;144(1):183-192. https://www.jacionline.org/article/S0091-6749(19)30210-6/fulltext.
• Park HJ, et al. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(8):2739-2749.e3. https://www.sciencedirect.com/science/article/abs/pii/S2213219819305434?via=ihub.
• Perkin MR, et al. Efficacy of the Enquiring About Tolerance (EAT) study among infants at high risk of developing food allergy. Journal of Allergy and Clinical Immunology. 2019;144(6):1606-1614.e2. https://www.jacionline.org/article/S0091-6749(19)31031-0/fulltext.


A5 Anaphylaxis


• Platts-Mills TAE, et al. Diagnosis and Management of Patients with the a-Gal Syndrome. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(1):15-23.e1. https://www.sciencedirect.com/science/article/pii/S2213219819307950?via%3Dihub
• Ramsey NB, et al. Epidemiology of Anaphylaxis in Critically Ill Children in the United States and Canada. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(7):2241-2249. https://www.sciencedirect.com/science/article/pii/S2213219819303988?via%3Dihub
• Weiler CR, et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. Journal of Allergy and Clinical Immunology. 2019;144(4):883-896. https://www.jacionline.org/article/S0091-6749(19)31116-9/fulltext


B1 Immune Hypersensitivity Disorders


• Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Annals of Allergy, Asthma & Immunology. 2019;123(5):454-460. https://www.annallergy.org/article/S1081-1206(19)30532-0/fulltext
• Fabre A, et al. Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1958-1969.e9. https://www.sciencedirect.com/science/article/abs/pii/S2213219819301941?via%3Dihub
• Sha BE. Adult Immunization Update. Journal of the American Medical Association. 2019;322(11):1096-1097. https://jamanetwork.com/journals/jama/article-abstract/2748767


B2 Immunodeficiencies


• Gupta S, et al. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases. Annals of Allergy, Asthma & Immunology. 2019;123(3):271-279.e1. https://www.annallergy.org/article/S1081-1206(19)30436-3/fulltext
• Romberg N, Lawrence MG. Birds of a feather Common variable immune deficiencies. Annals of Allergy, Asthma & Immunology. 2019;123(5):461-467. https://www.annallergy.org/article/S1081-1206(19)30547-2/fulltext
• Seidel M, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1763-1770. https://www.sciencedirect.com/science/article/abs/pii/S2213219819301680?via%3Dihub


B3 Eosinophilic or Gastrointestinal Disorders


• Groetch M, et al. Dietary Therapy and Nutrition Management of Eosinophilic Esophagitis: A Work Group Report of the American Academy of Allergy, Asthma, and Immunology. Journal of Allergy and Clinical Immunology: In Practice. 2017;5(2):312-324.e29. https://www.sciencedirect.com/science/article/abs/pii/S221321981730003X?via%3Dihub
• Steinbach EC, Hernandez M, Dellon ES. Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1483-1495. https://www.sciencedirect.com/science/article/abs/pii/S2213219818304136?via%3Dihub
• Wu EY, et al. Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1496-1504. https://www.sciencedirect.com/science/article/abs/pii/S2213219818304239?via%3Dihub

 

Planning Committee

Leonard B. Bacharier, MD FAAAAI
Vanderbilt University, Nashville, TN
Relevant relationships: AstraZeneca (speaker), DBV Technologies (consultant), GlaxoSmithKline (speaker), Novartis (speaker), Regeneron (speaker), Sanofi (speaker)

Faculty

Carla M. Davis, MD FAAAAI
Baylor College of Medicine, Houston, TX
Relevant relationships: TBD

Caroline Horner, MD FAAAAI
Washington University School of Medicine, St. Louis, MO
Relevant relationships: None

John Kelso, MD FAAAAI
Scripps Clinic, La Jolla, CA
Relevant relationships: None

Jennifer W, Leiding, MD FAAAAI
University of South Florida, Tampa, FL
Relevant relationships: TBD

All relevant relationships disclosed by planners and faculty have been mitigated.


AAAAI Disclosure Policy

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

  • Employment. Name of employer and job title.
  • Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
  • Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
  • Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
  • Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
  • Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
  • Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.

 

Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

Release date
Original release date: February 26, 2021. Valid for credit through December 31, 2021.

Questions
Activity-related questions should be directed to cme@aaaai.org.

Available Credit

  • 2.25 Attendance
    Attendance credit.
  • 2.25 CME
    CME credit.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

One of the two most recent versions of Chrome, Firefox, or Safari.

Internet Explorer is no longer supported.